Cargando…

Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study

BACKGROUND AND PURPOSE: Neurological sequelae from coronavirus disease 2019 (COVID‐19) may persist after recovery from acute infection. Here, the aim was to describe the natural history of neurological manifestations over 1 year after COVID‐19. METHODS: A prospective, multicentre, longitudinal cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Rass, Verena, Beer, Ronny, Schiefecker, Alois Josef, Lindner, Anna, Kofler, Mario, Ianosi, Bogdan Andrei, Mahlknecht, Philipp, Heim, Beatrice, Peball, Marina, Carbone, Federico, Limmert, Victoria, Kindl, Philipp, Putnina, Lauma, Fava, Elena, Sahanic, Sabina, Sonnweber, Thomas, Löscher, Wolfgang N., Wanschitz, Julia V., Zamarian, Laura, Djamshidian, Atbin, Tancevski, Ivan, Weiss, Günter, Bellmann‐Weiler, Rosa, Kiechl, Stefan, Seppi, Klaus, Loeffler‐Ragg, Judith, Pfausler, Bettina, Helbok, Raimund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111823/
https://www.ncbi.nlm.nih.gov/pubmed/35239247
http://dx.doi.org/10.1111/ene.15307
_version_ 1784709309332979712
author Rass, Verena
Beer, Ronny
Schiefecker, Alois Josef
Lindner, Anna
Kofler, Mario
Ianosi, Bogdan Andrei
Mahlknecht, Philipp
Heim, Beatrice
Peball, Marina
Carbone, Federico
Limmert, Victoria
Kindl, Philipp
Putnina, Lauma
Fava, Elena
Sahanic, Sabina
Sonnweber, Thomas
Löscher, Wolfgang N.
Wanschitz, Julia V.
Zamarian, Laura
Djamshidian, Atbin
Tancevski, Ivan
Weiss, Günter
Bellmann‐Weiler, Rosa
Kiechl, Stefan
Seppi, Klaus
Loeffler‐Ragg, Judith
Pfausler, Bettina
Helbok, Raimund
author_facet Rass, Verena
Beer, Ronny
Schiefecker, Alois Josef
Lindner, Anna
Kofler, Mario
Ianosi, Bogdan Andrei
Mahlknecht, Philipp
Heim, Beatrice
Peball, Marina
Carbone, Federico
Limmert, Victoria
Kindl, Philipp
Putnina, Lauma
Fava, Elena
Sahanic, Sabina
Sonnweber, Thomas
Löscher, Wolfgang N.
Wanschitz, Julia V.
Zamarian, Laura
Djamshidian, Atbin
Tancevski, Ivan
Weiss, Günter
Bellmann‐Weiler, Rosa
Kiechl, Stefan
Seppi, Klaus
Loeffler‐Ragg, Judith
Pfausler, Bettina
Helbok, Raimund
author_sort Rass, Verena
collection PubMed
description BACKGROUND AND PURPOSE: Neurological sequelae from coronavirus disease 2019 (COVID‐19) may persist after recovery from acute infection. Here, the aim was to describe the natural history of neurological manifestations over 1 year after COVID‐19. METHODS: A prospective, multicentre, longitudinal cohort study in COVID‐19 survivors was performed. At a 3‐month and 1‐year follow‐up, patients were assessed for neurological impairments by a neurological examination and a standardized test battery including the assessment of hyposmia (16‐item Sniffin' Sticks test), cognitive deficits (Montreal Cognitive Assessment < 26) and mental health (Hospital Anxiety and Depression Scale and Post‐traumatic Stress Disorder Checklist 5). RESULTS: Eighty‐one patients were evaluated 1 year after COVID‐19, out of which 76 (94%) patients completed a 3‐month and 1‐year follow‐up. Patients were 54 (47–64) years old and 59% were male. New and persistent neurological disorders were found in 15% (3 months) and 12% (10/81; 1 year). Symptoms at 1‐year follow‐up were reported by 48/81 (59%) patients, including fatigue (38%), concentration difficulties (25%), forgetfulness (25%), sleep disturbances (22%), myalgia (17%), limb weakness (17%), headache (16%), impaired sensation (16%) and hyposmia (15%). Neurological examination revealed findings in 52/81 (64%) patients without improvement over time (3 months, 61%, p = 0.230) including objective hyposmia (Sniffin' Sticks test <13; 51%). Cognitive deficits were apparent in 18%, whereas signs of depression, anxiety and post‐traumatic stress disorders were found in 6%, 29% and 10% respectively 1 year after infection. These mental and cognitive disorders had not improved after the 3‐month follow‐up (all p > 0.05). CONCLUSION: Our data indicate that a significant patient number still suffer from neurological sequelae including neuropsychiatric symptoms 1 year after COVID‐19 calling for interdisciplinary management of these patients.
format Online
Article
Text
id pubmed-9111823
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91118232022-05-17 Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study Rass, Verena Beer, Ronny Schiefecker, Alois Josef Lindner, Anna Kofler, Mario Ianosi, Bogdan Andrei Mahlknecht, Philipp Heim, Beatrice Peball, Marina Carbone, Federico Limmert, Victoria Kindl, Philipp Putnina, Lauma Fava, Elena Sahanic, Sabina Sonnweber, Thomas Löscher, Wolfgang N. Wanschitz, Julia V. Zamarian, Laura Djamshidian, Atbin Tancevski, Ivan Weiss, Günter Bellmann‐Weiler, Rosa Kiechl, Stefan Seppi, Klaus Loeffler‐Ragg, Judith Pfausler, Bettina Helbok, Raimund Eur J Neurol Infectious Diseases BACKGROUND AND PURPOSE: Neurological sequelae from coronavirus disease 2019 (COVID‐19) may persist after recovery from acute infection. Here, the aim was to describe the natural history of neurological manifestations over 1 year after COVID‐19. METHODS: A prospective, multicentre, longitudinal cohort study in COVID‐19 survivors was performed. At a 3‐month and 1‐year follow‐up, patients were assessed for neurological impairments by a neurological examination and a standardized test battery including the assessment of hyposmia (16‐item Sniffin' Sticks test), cognitive deficits (Montreal Cognitive Assessment < 26) and mental health (Hospital Anxiety and Depression Scale and Post‐traumatic Stress Disorder Checklist 5). RESULTS: Eighty‐one patients were evaluated 1 year after COVID‐19, out of which 76 (94%) patients completed a 3‐month and 1‐year follow‐up. Patients were 54 (47–64) years old and 59% were male. New and persistent neurological disorders were found in 15% (3 months) and 12% (10/81; 1 year). Symptoms at 1‐year follow‐up were reported by 48/81 (59%) patients, including fatigue (38%), concentration difficulties (25%), forgetfulness (25%), sleep disturbances (22%), myalgia (17%), limb weakness (17%), headache (16%), impaired sensation (16%) and hyposmia (15%). Neurological examination revealed findings in 52/81 (64%) patients without improvement over time (3 months, 61%, p = 0.230) including objective hyposmia (Sniffin' Sticks test <13; 51%). Cognitive deficits were apparent in 18%, whereas signs of depression, anxiety and post‐traumatic stress disorders were found in 6%, 29% and 10% respectively 1 year after infection. These mental and cognitive disorders had not improved after the 3‐month follow‐up (all p > 0.05). CONCLUSION: Our data indicate that a significant patient number still suffer from neurological sequelae including neuropsychiatric symptoms 1 year after COVID‐19 calling for interdisciplinary management of these patients. John Wiley and Sons Inc. 2022-03-23 2022-06 /pmc/articles/PMC9111823/ /pubmed/35239247 http://dx.doi.org/10.1111/ene.15307 Text en © 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Infectious Diseases
Rass, Verena
Beer, Ronny
Schiefecker, Alois Josef
Lindner, Anna
Kofler, Mario
Ianosi, Bogdan Andrei
Mahlknecht, Philipp
Heim, Beatrice
Peball, Marina
Carbone, Federico
Limmert, Victoria
Kindl, Philipp
Putnina, Lauma
Fava, Elena
Sahanic, Sabina
Sonnweber, Thomas
Löscher, Wolfgang N.
Wanschitz, Julia V.
Zamarian, Laura
Djamshidian, Atbin
Tancevski, Ivan
Weiss, Günter
Bellmann‐Weiler, Rosa
Kiechl, Stefan
Seppi, Klaus
Loeffler‐Ragg, Judith
Pfausler, Bettina
Helbok, Raimund
Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study
title Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study
title_full Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study
title_fullStr Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study
title_full_unstemmed Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study
title_short Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study
title_sort neurological outcomes 1 year after covid‐19 diagnosis: a prospective longitudinal cohort study
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111823/
https://www.ncbi.nlm.nih.gov/pubmed/35239247
http://dx.doi.org/10.1111/ene.15307
work_keys_str_mv AT rassverena neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT beerronny neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT schiefeckeraloisjosef neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT lindneranna neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT koflermario neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT ianosibogdanandrei neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT mahlknechtphilipp neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT heimbeatrice neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT peballmarina neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT carbonefederico neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT limmertvictoria neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT kindlphilipp neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT putninalauma neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT favaelena neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT sahanicsabina neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT sonnweberthomas neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT loscherwolfgangn neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT wanschitzjuliav neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT zamarianlaura neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT djamshidianatbin neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT tancevskiivan neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT weissgunter neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT bellmannweilerrosa neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT kiechlstefan neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT seppiklaus neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT loefflerraggjudith neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT pfauslerbettina neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy
AT helbokraimund neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy